PBAC Public Summary Documents – November 2024
Page last updated: 21 March 2025
Public Summary Documents relating to the November 2024 PBAC meeting.
- Abrocitinib , Tablet 50 mg, Tablet, 100 mg, Tablet 200 mg; Cibinqo
- Aflibercept (DMO); Solution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL) pre-filled syringe; Eylea®
- Aflibercept (nAMD); Solution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL) pre-filled syringe; Eylea®
- Amino Acid Formula with Fat, Carbohydrate, Vitamins and Minerals without Phenylalanine; Tablets (modified release), 54 g protein per 100 g, 100 g, pack of 6 (PKU Easy Microtabs Plus); PKU Easy Microtabs Plus
- Amino Acid Formula with Fat, Carbohydrate, Vitamins, Minerals, Trace Elements and Medium Chain Triglycerides; Oral powder 400 g (Essential Care Jr); Essential Care Jr
- Amino Acid Formula with Vitamins And Minerals Without Lysine and Low In Tryptophan; Sachets containing oral powder 12.5 g, pack of 30 (GA explore5); GA explore5™
- Amino Acid Formula with Vitamins And Minerals Without Methionine, Threonine And Valine and Low In Isoleucine; Sachets containing oral powder 12.5 g, pack of 30 (MMA/PA explore5); MMA/PA explore5™
- Amivantamab; Solution concentrate for I.V. infusion 350 mg in 7 mL; Rybrevant®
- Budesonide; Suppository 4 mg; Budenofalk®
- Capivasertib; Tablet 160 mg, Tablet 200 mg; Truqap®
- Clobetasol; Cream containing clobetasol propionate 500 micrograms per g, 30 g, Ointment containing clobetasol propionate 500 micrograms per g, 30 g; Xobet®
- Denosumab; Injection 60 mg in 1 mL pre-filled syringe; Jubbonti®; Injection 120 mg in 1.7 mL; Wyost®
- Drospirenone; Pack containing 24 tablets 4 mg and 4 inert tablets; Slinda®
- Enfortumab Vedotin; Powder for I.V. infusion 20 mg, Powder for I.V. infusion 30 mg; Padcev®
- Enzalutamide; Capsule 40 mg; Xtandi®
- Epcoritamab; Solution concentrate for subcutaneous injection 4 mg in 0.8 mL, Solution for subcutaneous injection 48 mg in 0.8 mL; Epkinly®
- Erenumab; Solution for subcutaneous injection 70 mg in 1 mL single dose pre-filled pen, Solution for subcutaneous injection 140 mg in 1 mL single dose pre-filled pen; Aimovig®
- Estradiol, Progesterone, Estradiol and Progesterone: Estradiol; Transdermal gel (pump pack) 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses; Estrogel®; Progesterone; Capsule 100 mg; Prometrium®; Estradiol and Progesterone; Pack containing transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses and 30 capsules progesterone 100 mg (micronised); Estrogel® Pro
- Fenfluramine; Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL; Fintepla®
- Fingolimod, Ofatumumab, Siponimod: Fingolimod; Capsule 250 micrograms (as hydrochloride) Capsule 500 micrograms (as hydrochloride); Gilenya®; Ofatumumab; Solution for injection 20 mg in 0.4 mL pre filled pen; Kesimpta®; Siponimod; Tablet 250 micrograms (as hemifumarate) Tablet 2 mg (as hemifumarate); Mayzent®
- Follitropin Alfa with Lutropin Alfa; Injection 900 I.U. - 450 I.U. in 1.44 mL multi dose cartridge; Pergoveris®
- Foslevodopa with Foscarbidopa; Solution for subcutaneous infusion foslevodopa 2400 mg with foscarbidopa 120 mg in 10 mL; Vyalev®
- Garadacimab; Injection 200 mg in 1.2 mL pre-filled pen; Andembry®
- Glycomacropeptide and Essential Amino Acids wth Vitamins and Minerals; Sachets containing oral powder 15 g, 30 (PKU Build 10); PKU Build 10
- Inclisiran (restriction level); Injection 284 mg in 1.5 mL single use pre-filled syringe; Leqvio®
- Inclisiran (NP prescribing); Injection 284 mg in 1.5 mL single use pre-filled syringe; Leqvio®
- IncobotulinumtoxinA; Lyophilised powder for injection 100 units; Xeomin®
- Irinotecan; Solution for I.V. infusion containing nanoliposomal irinotecan (as sucrosofate) 43 mg in 10 mL; Onivyde®
- Ivosidenib; Tablet 250 mg; Tibsovo®
- Lanadelumab; Injection 150 mg in 1 mL single use pre-filled syringe; Takhzyro®
- Leuprorelin; Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 7.5 mg, injection set, Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 22.5 mg, injection set, Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 30 mg, injection set, Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 45 mg, injection set; Eligard®
- Macitentan with Tadalafil; Tablet containing macitentan 10 mg with tadalafil 40 mg; Opsynvi®
- Maribavir; Tablet 200 mg; Livtencity®
- Momelotinib; Tablet 100 mg (as dihydrochloride monohydrate), Tablet 150 mg (as dihydrochloride monohydrate), Tablet 200 mg (as dihydrochloride monohydrate); Omjjara®
- Nintedanib; Capsule 100 mg, Capsule 150 mg, Ofev®
- Nivolumab; Injection concentrate for I.V. infusion 40 mg in 4 m L Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
- Olaparib; Tablet 100 mg, Tablet 150 mg; Lynparza®
- Palovarotene; Capsule 1 mg, Capsule 1.5 mg,Capsule 2.5 mg, Capsule 5 mg, Capsule 10 mg; Sohonos®
- Pembrolizumab; Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Ravulizumab; Solution concentrate for I.V. infusion 300 mg in 3 mL, Solution concentrate for I.V. infusion 1,100 mg in 11 mL; Ultomiris®
- Relugolix with Estradiol and with Norethisterone Acetate; Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 0.5 mg; Ryeqo®
- Respiratory Syncytial Virus Vaccine; Injection (0.5 mL);Abrysvo®
- Ribociclib; Tablet 200 mg; Kisqali®
- Rivaroxaban Tablet 2.5 mg, Tablet 10 mg; Xarelto®
- Sacubitril with Valsartan; Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg, Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg, Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg; Entresto®
- Semaglutide; Solution for injection 2 mg in 3 mL pre-filled pen; Ozempic®
- Tiotropium with Olodaterol; Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses, pack of 2; Spiolto® Respimat®
- Tiotropium; Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (2 x 60 actuations), pack of 2; Spiriva® Respimat®
- Tirzepatide; Solution for injection 2.5 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 5 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 7.5 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 10 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 12.5 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 15 mg in 0.5 mL vial/pre‑filled pen; Mounjaro®; Injection 4.17 milligrams per mL (2.5 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 8.33 milligrams per mL (5 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 12.5 milligrams per mL (7.5 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 16.67 milligrams per mL (10 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 20.83 milligrams per mL (12.5 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 25 milligrams per mL (15 mg per dose) in multi-dose pre-filled pen, 4 doses; Mounjaro® KwikPen®
- Tislelizumab; Solution concentrate for I.V. infusion 100 mg in 10 mL; Tevimbra®
- Triglycerides, Long Chain with Glucose Polymer; Oral liquid 1 L, 6 (ProZero); ProZero®
- Ustekinumab; Injection 45 mg in 0.5 mL single use pre-filled syringe, Injection 90 mg in 1 mL single use pre-filled syringe, Solution for I.V. infusion 130 mg in 26 mL; Steqeyma®
- Vutrisiran; Injection 25 mg (as sodium) in 0.5 mL pre filled syringe; Amvuttra®
The following Public Summary Documents have been updated:
July 2024 PBAC meeting
- Blinatumomab; Powder for I.V. infusion 38.5 micrograms; Blincyto®
- Drospirenone with Ethinylestradiol; Pack containing 24 tablets 3 mg drospirenone with 20 micrograms ethinylestradiol (as betadex clathrate) and 4 inert tablets; Yaz®; Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol (as betadex clathrate) and 7 inert tablets; Yasmin®
- Levodopa with Carbidopa and Entacapone; Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg and with entacapone 20 mg per mL, 47 mL; Lecigon®
